Page 182
CENTRAL ASIAN JOURNAL OF ACADEMIC
RESEARCH
IF = 5.441
Volume 3, Issue 05, Part 3 May 2025
www.in-academy.uz
THE APPLICATION OF SILIBUM MARIANUM GAERTN.L.
IN THE TREATMENT OF ONCOLOGICAL DISEASES
Saparniyazova Gulchekhra Islamovna
Student of Karakalpak Institute of
Agriculture and Agrotechnologies
https://doi.org/10.5281/zenodo.15523531
ARTICLE INFO
ABSTRACT
Qabul qilindi: 20-May 2025 yil
Ma’qullandi: 24- May 2025 yil
Nashr qilindi: 27-May 2025 yil
Silibum marianum Gaertn.L., commonly known as milk
thistle, has long been used in traditional medicine for its
hepatoprotective effects. Recent studies have expanded
its potential applications, highlighting its promising role
in the treatment and support of oncological diseases.
This article explores the pharmacological properties of
its primary bioactive compound, silymarin, with a
particular focus on its antioxidant, anti-inflammatory,
and anti-carcinogenic mechanisms. The advantages of
Silibum marianum over conventional therapies—such as
low toxicity, selective cytotoxicity against tumor cells,
and synergistic potential with chemotherapeutic
agents—are discussed in detail. Additionally, current
challenges including limited clinical evidence, low
bioavailability, and the need for standardized
formulations are addressed. The article concludes by
outlining future research directions and emphasizing the
plant’s potential as part of an integrative approach to
cancer care.
KEYWORDS
Silibum marianum, milk thistle,
silymarin,
cancer
therapy,
natural
compounds,
anti-
carcinogenic,
integrative
oncology,
low
toxicity,
phytotherapy, complementary
treatment.
Introduction.
In recent decades, oncological diseases have emerged as one of the
leading causes of morbidity and mortality globally. Despite the advancements in conventional
cancer therapies such as chemotherapy, radiotherapy, and immunotherapy, the search for
novel therapeutic agents continues unabated. In this context, natural compounds have gained
increasing attention for their potential to provide effective, safe, and affordable alternatives or
adjuvants to conventional treatments. Among these,
Silibum marianum
Gaertn.L., commonly
known as milk thistle, has shown promising pharmacological properties, especially in the
realm of hepatoprotection and anti-cancer activity. This article aims to explore the
phytochemical profile, mechanisms of action, and clinical relevance of
Silibum marianum
in
the treatment of oncological diseases, while also highlighting current research trends and
limitations.
To begin with, it is essential to understand the bioactive compounds responsible for the
medicinal properties of
Silibum marianum
. The plant seeds contain a complex of
flavonolignans collectively known as silymarin, which includes silybin (silibinin), silydianin,
Page 183
CENTRAL ASIAN JOURNAL OF ACADEMIC
RESEARCH
IF = 5.441
Volume 3, Issue 05, Part 3 May 2025
www.in-academy.uz
silychristin, and isosilybin. Notably, silybin is the most biologically active and extensively
studied component. Furthermore, the plant also comprises polyphenolic compounds, fatty
acids, tocopherols, and sterols, which contribute synergistically to its antioxidant, anti-
inflammatory, and anti-proliferative effects. Given this rich phytochemical profile,
Silibum
marianum
has attracted considerable interest from oncological researchers worldwide.
Several molecular pathways have been identified through which silymarin and its
components exert anti-cancer effects. These mechanisms include:
First and foremost,
Silibum marianum
exhibits powerful free radical scavenging activity,
which helps in mitigating oxidative stress, a known contributor to cancer development. By
neutralizing reactive oxygen species (ROS), it prevents DNA damage and genomic instability,
thereby reducing the risk of malignant transformation. In addition, silymarin promotes
programmed cell death (apoptosis) in various cancer cell lines, including breast, prostate,
liver, and colon cancers. It activates caspases, modulates Bcl-2 family proteins, and disrupts
mitochondrial membrane potential, leading to cancer cell apoptosis without harming normal
cells. Moreover, studies have shown that silymarin impedes cell cycle progression,
particularly by arresting cells in the G1 or G2/M phase. This effect is mediated through the
downregulation of cyclin-dependent kinases (CDKs) and cyclins, as well as the upregulation of
tumor suppressor proteins like p53. Furthermore, silymarin has been found to suppress
angiogenesis by inhibiting vascular endothelial growth factor (VEGF), thus depriving tumors
of blood supply. It also hampers metastasis by downregulating matrix metalloproteinases
(MMPs), thereby limiting cancer spread [3].
Although preclinical studies have provided compelling evidence for the anti-cancer
potential of
Silibum marianum
, its translation to clinical settings requires rigorous validation.
Nevertheless, several clinical trials and observational studies have been conducted,
particularly focusing on hepatocellular carcinoma (HCC) and chemotherapy-induced
hepatotoxicity. One of the most well-documented applications of
Silibum marianum
is in the
prevention and adjunct treatment of liver cancer. Notably, patients with chronic hepatitis B
and C infections, which are major risk factors for HCC, may benefit from silymarin’s
hepatoprotective and anti-proliferative effects. Clinical trials have demonstrated
improvement in liver enzyme profiles, reduced tumor progression, and enhanced survival
rates when silymarin is used alongside conventional therapies. In another significant
application, silymarin has been shown to protect normal tissues against the cytotoxic effects
of chemotherapy. For instance, patients undergoing cisplatin or doxorubicin treatment have
experienced reduced hepatic and renal toxicity with concurrent silymarin administration.
Although research is still in its nascent stages, preliminary findings suggest that silymarin
could serve as an adjuvant therapy in hormone-dependent cancers such as breast and
prostate cancers. Its ability to modulate estrogen receptors, inhibit androgen receptor
signaling, and reduce inflammatory cytokines presents exciting therapeutic prospects [2, 987-
993].
As the side effects of conventional cancer treatments remain a major concern, natural
remedies like
Silibum marianum
(milk thistle) are gaining attention as supportive agents. Its
main compound, silymarin, offers several notable advantages. Firstly,
Silibum marianum
has a
low toxicity profile, making it safer for long-term use. Unlike many chemotherapeutic drugs
that harm both cancerous and healthy cells, silymarin causes minimal damage to normal
Page 184
CENTRAL ASIAN JOURNAL OF ACADEMIC
RESEARCH
IF = 5.441
Volume 3, Issue 05, Part 3 May 2025
www.in-academy.uz
tissues, even at higher doses. Secondly, it shows selective action against tumor cells. Silymarin
targets cancer cells through its antioxidant, anti-inflammatory, and pro-apoptotic properties,
while largely sparing healthy cells, which reduces adverse effects. Thirdly, it has synergistic
potential. When combined with chemotherapy,
Silibum marianum
may enhance the efficacy of
drugs and protect organs like the liver from toxicity. This allows for better tolerance and
possibly improved outcomes. However, it is essential to stress that
Silibum marianum
should
be used as a complement, not a replacement, for conventional therapies. Its role lies in
integrative oncology—supporting treatment, not substituting it. In summary, the plant offers
promising support in cancer care due to its safety, selectivity, and compatibility with standard
treatments. Further research will help define its full potential in clinical practice.
Despite the promising therapeutic potential of
Silibum marianum
in oncology, several
challenges remain that must be addressed before it can be widely adopted in clinical practice.
While preclinical studies have demonstrated its anti-cancer properties, clinical evidence is
still limited. Most existing human studies focus on liver protection rather than direct anti-
tumor effects, highlighting a need for more comprehensive and large-scale clinical trials
targeting various cancer types. Another challenge lies in the standardization of dosage and
formulation. The bioavailability of silymarin is relatively low due to poor water solubility and
limited absorption in the gastrointestinal tract. As a result, consistent therapeutic outcomes
are difficult to achieve. Therefore, future research must focus on developing enhanced
delivery systems—such as nanoparticles, liposomes, or phytosome complexes—to improve
absorption and ensure consistent efficacy. In addition, potential drug interactions need to be
thoroughly investigated. As cancer patients often receive multiple medications, it is essential
to determine whether
Silibum marianum
interferes with or enhances the effects of
chemotherapy or other supportive drugs. Without this knowledge, the uncontrolled use of
herbal supplements could pose risks rather than offer benefits. Looking ahead,
interdisciplinary collaboration between pharmacologists, oncologists, and botanical
researchers will be key to integrating
Silibum marianum
into evidence-based cancer
treatment. Genomic and proteomic studies may also uncover new molecular targets, allowing
for more personalized approaches to therapy. Moreover, patient-centered research focusing
on quality of life and symptom management can help define the plant’s role in supportive
oncology care. In conclusion, while
Silibum marianum
shows great promise, overcoming
scientific and clinical hurdles will be essential for its acceptance in mainstream medicine.
With rigorous research and technological innovation, it may become a valuable component of
future integrative cancer therapies.
Conclusion.
To sum up,
Silibum marianum
Gaertn.L. holds significant potential in the
treatment of oncological diseases, particularly due to its antioxidant, anti-proliferative, and
hepatoprotective properties. While preclinical studies and early-phase clinical trials are
encouraging, further research is imperative to overcome current limitations and fully harness
the plant’s therapeutic power. In light of increasing interest in evidence-based phytotherapy,
Silibum marianum
represents a promising natural adjunct in cancer care—offering hope not
only for improved treatment outcomes but also for enhanced patient quality of life. As science
advances, a multidisciplinary approach that integrates traditional botanical knowledge with
modern medical research may pave the way for more effective and holistic cancer therapies in
the future.
Page 185
CENTRAL ASIAN JOURNAL OF ACADEMIC
RESEARCH
IF = 5.441
Volume 3, Issue 05, Part 3 May 2025
www.in-academy.uz
References:
1.
Abdraimova, K. Yu, A. R. Utepbergenova, and G. I. Saparniyazova. "STUDY
CHARACTERISTICS OF THE PLANT SILIBUM MARIANUM GAERTN. L." Академические
исследования в современной науке 4.13 (2025): 77-80.
2.
Abdurakhimov, Umorbek K., et al. "Biochemical Characteristics of Saint Mary’s Thistle
Varieties (Silybum marianum L. Gaertn.) under Soil-Climate Conditions of the Khorezm
Region." American Journal of Plant Sciences 11.7 (2020): 987-993.
3.
Alamdari, Ebrahim Gholamalipour, et al. "Evaluating the effect of allelopathic stress of
Silybum marianum Gaertn (L.) and Malva sylvestris L. on the cress (Lepidium sativum L.)
sensitive to allelochemicals in order to reduce environmental pollution." (2024).
4.
Saparniyazova, G. I. "Methods of analysis of the plant Silibum Marianum Gaertn. L."
American Journal Of Applied Science And Technology 5.03 (2025): 48-50.
5.
Sharipboyeva, Yulduz Muzafarovna, and Miriban Raimovna Askarova. "Analysis of the root
and root circumference nematode of silybum marianum (L) gaertn." ACADEMICIA: An
International Multidisciplinary Research Journal 12.5 (2022): 1236-1238.
